Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Last updated: February 3, 2021
Sponsor: Bayer
Overall Status: Completed

Phase

4

Condition

Pulmonary Arterial Hypertension

Stress

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT02891850
18588
2016-001067-36
  • Ages 18-75
  • All Genders

Study Summary

To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and female patients aged 18 to 75 years.
  • Patients with symptomatic PAH with a pulmonary vascular resistance (PVR) > 400dynseccm-5, mean pulmonary artery pressure ≥ 25 mmHg, and pulmonary capillary wedgepressure (PCWP) ≤ 15 mmHg as assessed by the most recent right heart catheterization (RHC) from medical history prior to screening to confirm the diagnosis. Alternatively,PCWP can be replaced by left ventricular end-diastolic pressure (≤ 15 mmHg). PAH ofthe following types:
  • Idiopathic
  • Hereditary
  • Drug and toxin induced PAH
  • Associated with PAH due to:
  • Connective tissue disease (CTD)
  • Congenital heart disease, but only if the patient underwent surgical repairmore than one year before enrolment
  • Portal hypertension with liver cirrhosis (Note: patients with clinicalrelevant hepatic dysfunction are excluded; see exclusions related todisorders in organ function)
  • Patients who are on stable doses of a PDE-5i and ERA combination therapy or on stablePDE-5i monotherapy 6 weeks prior to and at randomization but not at treatment goal (tadalafil 20 to 40 mg once daily or sildenafil at least 60 mg daily dose).
  • WHO FC III at screening and at randomization.
  • 6MWD test between 165 m and 440 m at screening and at randomization.
  • Stable dose of diuretics, if used, for at least 30 days prior to and at randomization.
  • Patients who are able to understand and follow instructions and who are able toparticipate in the study for the entire study.
  • Women of childbearing potential must agree to use adequate contraception when sexuallyactive. Adequate contraception is defined as any combination of at least 2 effectivemethods of birth control, of which at least 1 is a physical barrier (e.g. condom withhormonal contraception like implants or combined oral contraceptives, condom withintrauterine devices). This applies beginning with signing of the informed consentform until 30 (+5) days after the last administration of study drug.
  • Patients must have given their written informed consent to participate in the studyafter having received adequate previous information and prior to any study-specificprocedures.

Exclusion

Exclusion Criteria:

  • Participation in another interventional clinical study within 30 days prior toscreening.
  • All types of PH (including PH-IIP) except subtypes of Dana Point Group I specified inthe inclusion criteria.
  • Previous treatment with riociguat.
  • Pregnant women (i.e., positive serum ß-human-chorionic-gonadotropin test or othersigns of pregnancy), or breast feeding women, or women with childbearing potential notusing a combination of 2 effective contraception methods (as laid out in inclusioncriterion) throughout the study.
  • Patients with a medical disorder, condition, or history of such that would impair thepatient's ability to participate or complete this study, in the opinion of theinvestigator.
  • Relevant obstructive and restrictive or other lung diseases.
  • Patients with underlying medical disorders with an anticipated life expectancy below 2years (e.g., active cancer disease with localized and/or metastasized tumor mass).
  • Cardiovascular exclusion criteria like left ventricular disease, coronary heartdisease or stroke within previous 3 months.
  • Patients with hypersensitivity to the investigational drug or any of the excipients.
  • Patients unable to perform a valid 6MWD test (e.g., orthopedic disease, peripheralartery occlusive disease, which affects the patient's ability to walk). Note:Patients, who require walking aids, may be included if in the opinion of theinvestigator the walking distance is not impaired. Patients with a variance of morethan 15% between the screening and the randomization (i.e., baseline) 6MWD test.

Study Design

Total Participants: 225
Study Start date:
January 11, 2017
Estimated Completion Date:
March 03, 2020

Study Description

Data from a previous single arm study (RESPITE) indicate that transition from PDE5i to riociguat may be feasible, safe and beneficial in patients not adequately responding to PDE5i.

REPLACE is a randomized controlled study to confirm the potential clinical benefit of transition from PDE5i to riociguat. Satisfactory clinical response in patients who are on a stable dose of phosphodiesterase-5inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal will be compared between one group of patients randomized to maintain current treatment and another group where the PDE5i is replaced by riociguat.

Connect with a study center

  • empty

    Camperdown, New South Wales 2050
    Australia

    Site Not Available

  • empty

    Chermside, Queensland 4032
    Australia

    Site Not Available

  • Graz, 8036
    Austria

    Site Not Available

  • empty

    Innsbruck, 6020
    Austria

    Site Not Available

  • empty

    Wien, 1090
    Austria

    Site Not Available

  • empty

    Bruxelles - Brussel, 1070
    Belgium

    Site Not Available

  • Leuven, 3000
    Belgium

    Site Not Available

  • empty

    Brasília, Distrito Federal 70840 901
    Brazil

    Site Not Available

  • Belo Horizonte, Minas Gerais 30441-070
    Brazil

    Site Not Available

  • Porto Alegre, Rio Grande Do Sul 90050-170
    Brazil

    Site Not Available

  • Blumenal, Santa Catarina 89030-101
    Brazil

    Site Not Available

  • empty

    Rio de Janeiro, 21949 900
    Brazil

    Site Not Available

  • Sao Paulo, 05403-000
    Brazil

    Site Not Available

  • empty

    Calgary, Alberta T1Y 6J4
    Canada

    Site Not Available

  • empty

    Vancouver, British Columbia V5Z 1M9
    Canada

    Site Not Available

  • empty

    Ottawa, Ontario K1Y 4W7
    Canada

    Site Not Available

  • empty

    Toronto, Ontario M5G 2N2
    Canada

    Site Not Available

  • Montreal, Quebec H3T 1E2
    Canada

    Site Not Available

  • Praha 2, 12808
    Czechia

    Site Not Available

  • Praha 4, 140 21
    Czechia

    Site Not Available

  • Aarhus N, 8200
    Denmark

    Site Not Available

  • empty

    København Ø, 2100
    Denmark

    Site Not Available

  • empty

    Besancon, 25030
    France

    Site Not Available

  • empty

    GRENOBLE Cedex 09, 38043
    France

    Site Not Available

  • Le Kremlin-Bicêtre, 94270
    France

    Site Not Available

  • empty

    Lille Cedex, 59037
    France

    Site Not Available

  • Rouen, 76031
    France

    Site Not Available

  • Heidelberg, Baden-Württemberg 69126
    Germany

    Site Not Available

  • München, Bayern 81377
    Germany

    Site Not Available

  • Würzburg, Bayern 97074
    Germany

    Site Not Available

  • Hannover, Niedersachsen 30625
    Germany

    Site Not Available

  • Köln, Nordrhein-Westfalen 50937
    Germany

    Site Not Available

  • Homburg, Saarland 66421
    Germany

    Site Not Available

  • Dresden, Sachsen 01307
    Germany

    Site Not Available

  • Leipzig, Sachsen 04103
    Germany

    Site Not Available

  • Lübeck, Schleswig-Holstein 23538
    Germany

    Site Not Available

  • Berlin, 14050
    Germany

    Site Not Available

  • Gießen, 35390
    Germany

    Site Not Available

  • Hamburg, 20246
    Germany

    Site Not Available

  • Chaidari, 124 62
    Greece

    Site Not Available

  • empty

    Haidari, 124 62
    Greece

    Site Not Available

  • Thessaloniki, 546 36
    Greece

    Site Not Available

  • Napoli, Campania 80131
    Italy

    Site Not Available

  • Roma, Lazio 00161
    Italy

    Site Not Available

  • Pavia, Lombardia 27100
    Italy

    Site Not Available

  • Palermo, Sicilia 90127
    Italy

    Site Not Available

  • Nagoya, Aichi 467-8602
    Japan

    Site Not Available

  • Sendai, Miyagi 980-8574
    Japan

    Site Not Available

  • Bunkyo-ku, Tokyo 113-8655
    Japan

    Site Not Available

  • Seoul, 135-710
    Korea, Republic of

    Site Not Available

  • Culiacan, Sinaloa 80020
    Mexico

    Site Not Available

  • Mexico D.F., 14080
    Mexico

    Site Not Available

  • Amsterdam, 1081 HV
    Netherlands

    Site Not Available

  • Nijmegen, 6500HB
    Netherlands

    Site Not Available

  • empty

    Lodz, 91-347
    Poland

    Site Not Available

  • empty

    Otwock, 05-400
    Poland

    Site Not Available

  • Wroclaw, 51-124
    Poland

    Site Not Available

  • Almada, Lisboa 2801-951
    Portugal

    Site Not Available

  • Coimbra, 3000-075
    Portugal

    Site Not Available

  • Lisboa, 1649-035
    Portugal

    Site Not Available

  • Las Palmas de Gran Canaria, Las Palmas 35020
    Spain

    Site Not Available

  • empty

    La Laguna, Santa Cruz de Tenerife 38320
    Spain

    Site Not Available

  • Barcelona, 08035
    Spain

    Site Not Available

  • empty

    Madrid, 28041
    Spain

    Site Not Available

  • empty

    Salamanca, 37007
    Spain

    Site Not Available

  • Toledo, 45004
    Spain

    Site Not Available

  • empty

    Genève, 1205
    Switzerland

    Site Not Available

  • empty

    Zürich, 8091
    Switzerland

    Site Not Available

  • Kaoshiung, 81346
    Taiwan

    Site Not Available

  • Tainan, 704
    Taiwan

    Site Not Available

  • Taipei, 10016
    Taiwan

    Site Not Available

  • Ankara, 06100
    Turkey

    Site Not Available

  • Istanbul, 34093
    Turkey

    Site Not Available

  • Izmir, 34098
    Turkey

    Site Not Available

  • empty

    Cambridge, Cambridgeshire CB23 3RE
    United Kingdom

    Site Not Available

  • empty

    Bath, Somerset BA1 3NG
    United Kingdom

    Site Not Available

  • Clydebank, West Dunbartonshire G81 4DY
    United Kingdom

    Site Not Available

  • London, SW3 6NP
    United Kingdom

    Site Not Available

  • Sheffield, S10 2JF
    United Kingdom

    Site Not Available

  • Phoenix, Arizona 85012
    United States

    Site Not Available

  • Tucson, Arizona 85724
    United States

    Site Not Available

  • Sacramento, California 95817
    United States

    Site Not Available

  • empty

    New Haven, Connecticut 06520
    United States

    Site Not Available

  • Orlando, Florida 32803
    United States

    Site Not Available

  • Weston, Florida 33331
    United States

    Site Not Available

  • empty

    Chicago, Illinois 60612
    United States

    Site Not Available

  • empty

    Oak Lawn, Illinois 60453
    United States

    Site Not Available

  • Kansas City, Kansas 66103
    United States

    Site Not Available

  • Louisville, Kentucky 40202
    United States

    Site Not Available

  • empty

    Boston, Massachusetts 02114-2696
    United States

    Site Not Available

  • empty

    Ann Arbor, Michigan 48109-0330
    United States

    Site Not Available

  • Detroit, Michigan 48202
    United States

    Site Not Available

  • Troy, Michigan 48085
    United States

    Site Not Available

  • empty

    Saint Louis, Missouri 63110
    United States

    Site Not Available

  • empty

    St, Louis, Missouri 63110
    United States

    Site Not Available

  • Newark, New Jersey 07112
    United States

    Site Not Available

  • Mineola, New York 11501
    United States

    Site Not Available

  • New York, New York 10003
    United States

    Site Not Available

  • Rochester, New York 14623
    United States

    Site Not Available

  • empty

    Chapel Hill, North Carolina 27599
    United States

    Site Not Available

  • Cleveland, Ohio 44195
    United States

    Site Not Available

  • empty

    Columbus, Ohio 43210-1240
    United States

    Site Not Available

  • empty

    Pittsburgh, Pennsylvania 15212
    United States

    Site Not Available

  • Nashville, Tennessee 37232
    United States

    Site Not Available

  • Dallas, Texas 75390
    United States

    Site Not Available

  • empty

    Falls Church, Virginia 22042
    United States

    Site Not Available

  • Richmond, Virginia 23225
    United States

    Site Not Available

  • empty

    Seattle, Washington 98195
    United States

    Site Not Available

  • empty

    Milwaukee, Wisconsin 53215
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.